Current issue #23, 2016

Genetic scientists looking for ways to enter medical insurance programs

Providers of medical and genetic diagnostics services try to come to terms with insurance companies persuading them to follow the developed countries and let genetics take its rightful place in the Russian healthcare system. The Institute of Human Stem Cells initiated a meeting with scientists and insurers in order to prove using appropriate data that the government struggling for a healthy nation had to switch its focus to genetics. Thus, it will be possible to decrease the number of people born with severe pathologies.

[PharmVestnik # 23, 19/07/2016, p. 1, cont’d p. 4]

Premier D. Medvedev checks how import substitution is being implemented

The Government Import Substitution Commission meets every three to five months. As a rule, the Prime Minister who is the Commission chairperson, visits specific industrial facilities prior to such meetings in order to see examples of import substitution with his own eyes. The July meeting centered on the pharmaceutical and medical industry. Before that, Dmitry Medvedev was invited to visit the well-known Bakulev Scientific Center for Cardiovascular Surgery.

[PharmVestnik # 23, 19/07/2016, p. 2]

A drug marking pilot project to start in early 2017

Reportedly, in January 2017, the Ministry of Finance and Ministry of Health intend to launch a drug marking pilot project. Six Russian and foreign companies have been already selected for participation in this project. At the same time, many introductory provisions have not been determined yet. Even the pilot project participants themselves differ on what they were going to mark, and what type of information they were expected to use for marking. However, they agreed that the best drug marking type was the DataMatrix Code.

[PharmVestnik # 23, 19/07/2016, p. 3]

FAS explained what pharmacies and wholesalers were to do if registered drug prices were cancelled

In early June, the Russian Federal Antimonopoly Service (FAS) for the first time revoked the decision on drug price coordination made in 2015 by the Federal Tariff Service (FTS). The FAS officials noticed that PRO.MED.CS Praha a.s., the Ursosan manufacturer, executed the relevant documents in such a way that the FTS officers thought it went not about price re-regist...